4586 Medrx
- 83
- 00.00%
Medrx News
Medrx: Notice regarding the monthly exercise status of the 29th Stock Acquisition Rights (with exercise price amendment clause) issued by third party allotment
Medrx: Notice regarding the recording of non-operating expenses
Medrx: Summary of Financial Results for the 3rd Quarter Ending 2024/12 [Japanese GAAP] (Consolidated)
Medrx: Notice regarding the monthly exercise status of the 29th Stock Acquisition Rights (with exercise price amendment clause) issued by third party allotment
Medrx: Notice of commencement of MRX-7MLL clinical trials
Medrx: Notice regarding the monthly exercise status of the 29th Stock Acquisition Rights (with exercise price amendment clause) issued by third party allotment
Medrx: Notice Concerning Mass Exercise of the 29th Stock Acquisition Rights (with Exercise Price Amendment Clauses) Issued by Third Party Allotment
Medrx: Notice regarding the Reiwa 6th SME Overseas Expansion Support Project Cost Subsidy (Overseas Application Support Project) Indirect Subsidy Grant Decision
Medrx: Notice of Patent Assessment (Japan) relating to MRX-4TZT
Medrx: Change Report (short-term mass transfer)
Medrx: Notice regarding the monthly exercise status of the 29th Stock Acquisition Rights (with exercise price amendment clause) issued by third party allotment
Medrx: Change Report
Medrx: Financial results presentation for the second quarter of the fiscal year ending December 2024.
Medrx: Change Report
Medrx: Announcement of the massive exercise of the 29th subscription rights (with an exercise price adjustment clause) issued by third-party allotment.
Medrx: Change Report
Medrx: Announcement of the massive exercise of the 29th subscription rights (with an exercise price adjustment clause) issued by third-party allotment.
Medrx: Confirmatory letter.
Medrx: Announcements of individual stocks regarding the modification clause of the exercise price by third-party allocation and the 25th, 28th, and 29th subscription rights, and the change in the expected timing of expenditure of procurement funds.
Medrx: Announcement of differences between financial estimates and actual results for the second quarter (interim period) of the fiscal year ending December 2024.
No Data